{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:39:45Z","timestamp":1777520385173,"version":"3.51.4"},"reference-count":37,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Can J Psychiatry"],"published-print":{"date-parts":[[2008,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To examine whether subjective well-being and craving for cannabis were different in patients with schizophrenia or related disorders treated with either olanzapine or risperidone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method:<\/jats:title>\n                    <jats:p>A 6-week, double-blind, randomized trial of olanzapine and risperidone was carried out in 128 young adults with recent onset schizophrenia or related disorders. Primary efficacy measures were the mean baseline-to-endpoint change in total scores on the Subjective Well-Being under Neuroleptics scale, the Obsessive\u2013Compulsive Drug Use Scale, the Drug Desire Questionnaire, and the cannabis use self-report. An analysis of covariance was used to test between-group differences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Estimated D\n                      <jats:sub>2<\/jats:sub>\n                      receptor occupancy did not differ between olanzapine ( n = 63) and risperidone ( n = 65). Similar improvements in subjective well-being were found in both groups. In the comorbid cannabis-using group ( n = 41, 32%), a similar decrease in craving for cannabis was found in both treatment conditions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      Both olanzapine and risperidone were associated with improved subjective well-being. No evidence was found for a differential effect of olanzapine or risperidone on subjective experience or on craving for cannabis in dosages leading to comparable dopamine D\n                      <jats:sub>2<\/jats:sub>\n                      occupancy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectif:<\/jats:title>\n                    <jats:p>Examiner si le bien-\u00eatre subjectif et l'\u00e9tat de manque de cannabis \u00e9taient diff\u00e9rents chez les patients souffrant de schizophr\u00e9nie ou de troubles connexes trait\u00e9s \u00e0 l'olanzapine ou \u00e0 la risp\u00e9ridone.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/070674370805300610","type":"journal-article","created":{"date-parts":[[2017,7,20]],"date-time":"2017-07-20T01:42:19Z","timestamp":1500514939000},"page":"400-405","source":"Crossref","is-referenced-by-count":40,"title":["Effect of Olanzapine and Risperidone on Subjective Well-Being and Craving for Cannabis in Patients with Schizophrenia or Related Disorders: A Double-Blind Randomized Controlled Trial"],"prefix":"10.1177","volume":"53","author":[{"given":"Lonneke J","family":"van Nimwegen","sequence":"first","affiliation":[{"name":"Resident, Erasmus Medical Center, Rotterdam, the Netherlands; Resident, Academic Medical Center, University of Amsterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lieuwe","family":"de Haan","sequence":"additional","affiliation":[{"name":"Senior Consultant, Adolescent Clinic of the Academic Medical Center, University of Amsterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nico JM","family":"van Beveren","sequence":"additional","affiliation":[{"name":"Psychiatrist, Erasmus Medical Center, Rotterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mischa","family":"van der Helm","sequence":"additional","affiliation":[{"name":"Clinical Psychologist, Parnassia Psycho Medical Center, The Hague, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wim","family":"van den Brink","sequence":"additional","affiliation":[{"name":"Professor, Amsterdam Institute for Addiction Research, Academic Medical Center, Amsterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Don","family":"Linszen","sequence":"additional","affiliation":[{"name":"Professor and Head, Adolescent Clinic of the Academic Medical Center, University of Amsterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2008,6,1]]},"reference":[{"key":"bibr1-070674370805300610","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/23.4.637"},{"key":"bibr2-070674370805300610","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1981.01780270073010"},{"key":"bibr3-070674370805300610","doi-asserted-by":"publisher","DOI":"10.1055\/s-2003-45128"},{"key":"bibr4-070674370805300610","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2005.00542.x"},{"key":"bibr5-070674370805300610","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0447.2002.02437.x"},{"key":"bibr6-070674370805300610","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(01)00249-3"},{"key":"bibr7-070674370805300610","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2005.00554.x"},{"key":"bibr8-070674370805300610","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.157.6.1019"},{"key":"bibr9-070674370805300610","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.2.303"},{"key":"bibr10-070674370805300610","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.3.360"},{"key":"bibr11-070674370805300610","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(00)00166-3"},{"key":"bibr12-070674370805300610","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/16.1.31"},{"key":"bibr13-070674370805300610","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.schbul.a033339"},{"key":"bibr14-070674370805300610","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1990.03450190043026"},{"key":"bibr15-070674370805300610","doi-asserted-by":"publisher","DOI":"10.1007\/BF02190250"},{"key":"bibr16-070674370805300610","first-page":"26","volume":"52","author":"Cleghorn JM","year":"1991","journal-title":"J Clin Psychiatry"},{"key":"bibr17-070674370805300610","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291700010278"},{"key":"bibr18-070674370805300610","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1994.03950040017002"},{"key":"bibr19-070674370805300610","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/16.1.69"},{"key":"bibr20-070674370805300610","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1992.tb01456.x"},{"key":"bibr21-070674370805300610","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000085412.08426.08"},{"key":"bibr22-070674370805300610","doi-asserted-by":"publisher","DOI":"10.1007\/BF02246063"},{"key":"bibr23-070674370805300610","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-005-0218-x"},{"key":"bibr24-070674370805300610","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(94)00365-A"},{"key":"bibr25-070674370805300610","doi-asserted-by":"publisher","DOI":"10.3109\/10673229909017206"},{"key":"bibr26-070674370805300610","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300264"},{"key":"bibr27-070674370805300610","first-page":"407","volume":"175","author":"Hutchison KE","year":"2004","journal-title":"Psychopharmacology"},{"key":"bibr28-070674370805300610","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(03)00009-7"},{"key":"bibr29-070674370805300610","doi-asserted-by":"publisher","DOI":"10.1097\/01.nmd.0000165089.14736.bf"},{"key":"bibr30-070674370805300610","doi-asserted-by":"publisher","DOI":"10.1177\/070674370204700710"},{"key":"bibr31-070674370805300610","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2004.03.009"},{"key":"bibr32-070674370805300610","first-page":"133","volume":"10","author":"Naber D.","year":"1995","journal-title":"Int Clin Psychopharmacol"},{"key":"bibr33-070674370805300610","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-002-1054-x"},{"key":"bibr34-070674370805300610","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4603(01)00201-5"},{"key":"bibr35-070674370805300610","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-004-2010-8"},{"key":"bibr36-070674370805300610","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000194624.07611.5e"},{"key":"bibr37-070674370805300610","doi-asserted-by":"publisher","DOI":"10.1007\/s002130000629"}],"container-title":["The Canadian Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/070674370805300610","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/070674370805300610","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:11:24Z","timestamp":1777392684000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/070674370805300610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["10.1177\/070674370805300610"],"URL":"https:\/\/doi.org\/10.1177\/070674370805300610","relation":{},"ISSN":["0706-7437","1497-0015"],"issn-type":[{"value":"0706-7437","type":"print"},{"value":"1497-0015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}